Cravath’s New York Office Moves to Two Manhattan West
On February 13, 2025, Cravath partner Nicholas A. Dorsey participated in the International Bar Association’s 6th Silicon Hills Conference – the Tech Epicentre of Texas: from Start‑Up to Exit, which was held from February 12‑14 in Austin, Texas. Nick spoke on a panel entitled “Investing in Tech Startups. Is it Still Worth it?,” which explored investors’ skepticism around tech startups, the current and future M&A environment’s effect on exit valuations, the regulatory environment’s effect on international startup investments and whether investors should look to ventures beyond the tech industry.
Deals & Cases
February 03, 2025
On February 3, 2025, Outbrain Inc. (“Outbrain”), a technology platform, announced the closing of its acquisition of Teads, a global omnichannel platform, from Altice. The two companies will merge their offerings to create an omnichannel outcomes platform for the open internet, and will operate under the name Teads. Outbrain, Altice and Teads have amended the previously announced share purchase agreement. Under the terms of the revised agreement, Outbrain will be paying a total consideration of approximately $900 million, consisting of $625 million upfront cash and 43.75 million shares of common stock of Outbrain valued at approximately $263 million. Cravath is representing Outbrain in connection with the transaction.
Deals & Cases
January 06, 2025
On January 6, 2025, The Walt Disney Company (“Disney”) and FuboTV Inc. (“Fubo) announced that they have entered into a definitive agreement for Disney to combine its Hulu + Live TV business with Fubo, forming a combined virtual MVPD company of which Disney will become the majority owner.
Deals & Cases
November 04, 2024
On November 4, 2024, DRI Healthcare Trust (“the Trust”), a global leader in providing financing to advance innovation in the life sciences industry, announced it has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat, an investigational oral plasma kallikrein inhibitor for the treatment of Hereditary Angioedema, from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to $179 million, comprised of a $100 million upfront payment, up to $57 million in a sales-based milestone payment and a one-time $22 million optional payment. Additionally, the Trust is making a $5 million investment in KalVista’s common stock in a private placement transaction. Cravath is representing DRI Healthcare Trust in connection with the transaction.
Deals & Cases
October 11, 2024
Cravath represented the underwriters in connection with the $9 billion registered senior notes offering of Hewlett Packard Enterprise Company, an industry leading technology company. Proceeds of the offering were used to finance the acquisition of Juniper Networks, Inc. The transaction closed on September 26, 2024.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.